The Platform Charges What the Clinic Cannot Certify
The Authority That Was Priced
Peter Attia's Epstein email correspondence, reported this month, does not establish a clinical verdict. It documents a capital-credibility network. Attia's practice (Early Medical) and his widely distributed podcast were built on the implicit claim that one physician's synthesis of the literature carries clinical weight beyond what standard care offers. That claim has never been tested against a prospectively enrolled cohort with a defined primary endpoint. The emails document the access through which the authority was assembled.
A Stat News analysis this week drew on research by Saul Newman at the Australian National University demonstrating that centenarian prevalence in the blue zones (geographic areas journalist Dan Buettner has designated since the 2000s as having exceptional concentrations of people aged 100 or older) correlates with poor civil birth and death registration, not with confirmed lifespan at death. Buettner's brand (books, a Netflix documentary, municipal programs licensed to cities across the United States and internationally) was priced on that demographic signal. Newman's work has circulated in peer-reviewed and preprint forms since 2019. It attributes the signal to registration quality.
Vonda Wright, an orthopedic surgeon who has built a media presence on strength training and female aging, names her endpoints more precisely than most: sarcopenia prevention, peak muscle force maintenance. Both have published observational evidence behind them. Wright operates in the same influencer-physician economy as Attia; the market does not price the endpoint specificity separately.
Who Runs the Trial
BPC-157 (Body Protection Compound-157, a synthetic peptide with no approved therapeutic indication in any G7 jurisdiction and no completed Phase 1 human safety trial with published endpoints) is now being self-injected by patients who cite influencer-physician podcasts as their clinical reference. TB-500 (Thymosin Beta-4 fragment, a synthetic derivative of a naturally occurring thymic protein) holds the same regulatory status: no Investigational New Drug application filed with the FDA, no Clinical Trial Authorisation submitted to the EMA, and no application before Singapore's Health Sciences Authority (HSA, the city-state's pharmaceutical and health product regulator). Both are sold legally as research chemicals. Neither has cleared Phase 1.
The influencer-physician infrastructure implies otherwise: podcast segments on peptide dosing protocols, compounding pharmacist guest appearances, and anecdata positioned as n-of-1 evidence. A report published this week described practicing physicians raising alarm about the DIY injection trend and cited no regulatory response from any jurisdiction. Patients across Singapore and the broader region are injecting these compounds based on that implied framing. The capital is pricing a therapeutic. The trial has not been run.
I sat in on a diligence call in 2023 for a Singapore-based Series B biotech whose lead candidate was a synthetic peptide being positioned through a physician-influencer channel. The clinical lead could not name the primary endpoint of the Phase 1 study. No Phase 1 had been initiated.
Singapore's Health Sciences Authority shows no entry for BPC-157 or TB-500 in its controlled drugs and prescription-only medicines register as of May 2026. The FDA's Center for Drug Evaluation and Research (CDER, the division responsible for pharmaceutical scheduling decisions) has issued warning letters to peptide compounding vendors and stopped short of a formal scheduling classification. The question resolves when HSA or CDER acts, or when the first serious adverse event report is filed. The patient is already enrolled.